Taros achieved ELF milestone
30,000 novel chemical compounds shipped to the ELF
Taros Chemicals, a privately owned CRO focused on serving the needs of pharmaceutical, chemical, agrochemical and biotech companies, announced that in November this year, it achieved the benchmark of the delivery of 30,000 unprecedented chemical compounds to be used for high throughput screening within the unique Joint European Compound Library (JECL), part of the European Lead Factory (ELF).
Taros Chemicals, a leading European custom research and manufacturing organization announced it is robustly progressing through year 4 of the 5 years’ ELF project duration.
With over 30,000 compounds delivered into the Joint European Compound Library by January 2017, Taros is currently leading the SME contribution of novel screening compounds to the ELF collection.
A distinctive characteristic of the Taros’ screening compounds is its high level of structural complexity and three-dimensionality, two features that are regarded as attractive in drug discovery application. Taros Chemicals takes the challenge to design and synthesize unprecedented spiro, bridge and fused polycycles with different degrees of saturation, conjugation and substitution patterns. The finalized scaffolds with high three-dimensional character provide versatile starting points and ample opportunities for further chemical exploration and growth during the hit-to-lead phase.
The European Lead Factory (ELF) [current publication, PDF, co-authored by Dr. Dimitrios Tzalis, Taros] initiated in January 2013, is a €196 million Public Private Partnership (PPP) suppoted by the Innovative Medicines Initiative (IMI) and is aimed at boosting the initial phases of the drug discovery process. Pharmaceutical companies, academic groups and five Discovery small and medium-sized enterprises (SMEs) have formed a pan-European consortium to address the challenge of delivering an innovative, publicly-accessible, screening deck of synthetically-tractable compounds, named the Public Compound Collection (PCC). As part of the ELF, the seven participating pharmaceutical companies have contributed over 300,000 chemical compounds from their corporate chemical collections and the academic and SME members will deliver up to 200,000 compounds from unprecedented areas of biologically-relevant chemical space.
About Taros Chemicals
Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de
As a leading contract research organization in discovery chemistry and custom synthesis, Taros provides comprehensive solutions to meet our clients’ needs from diverse branches and applications
Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations, despite challenges, bridging very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project, starting from the development of synthetic routes to…